Please login to the form below

Not currently logged in
Email:
Password:

haemophilia

This page shows the latest haemophilia news and features for those working in and with pharma, biotech and healthcare.

Pfizer doses first patient in investigational haemophilia drug trial

Pfizer doses first patient in investigational haemophilia drug trial

Company is evaluating marstacimab in severe haemophilia A/B patients. Pfizer has dosed the first patient in its phase 3 study of marstacimab, an investigational drug being evaluated for the treatment ... Marstacimab offers a new way of treating

Latest news

More from news
Approximately 68 fully matching, plus 151 partially matching documents found.

Latest Intelligence

  • Keeping up with the developing regulatory requirements for gene and cell therapies Keeping up with the developing regulatory requirements for gene and cell therapies

    That’s why developers have started exploring other techniques, for example using a baculovirus with an insect producer cell, as done by BioMarin to produce its gene therapy for haemophilia.

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    If approved, Valrox would be the first potentially curative approach to haemophilia A, eliminating the need for blood transfusions and FVIII replacement therapy after a single infusion. ... The haemophilia market is conservative in adopting new therapies,

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    pipeline. The company submitted its lumasiran candidate for primary hyperoxaluria to the FDA and has another ATTR amyloidosis candidate – called vutrisiran – in late-stage along with Sanofi-partnered fitusiran for haemophilia

  • Novo Nordisk awakens its ‘Sleeping Beauty’ Novo Nordisk awakens its ‘Sleeping Beauty’

    The company is now projecting long-term improvements across its two main areas of haemophilia and growth hormone disorders, with confidence radiating into all quarters of its business. ... Competition is real life. Haemophilia is a crowded market and

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    The success or failure of Bluebird will be closely watched by a slew of cell and gene therapy companies including Sangamo, BioMarin (with exciting potential cures for haemophilia) and UniQure, looking ... to learn from its own mistakes with therapies for

More from intelligence
Approximately 1 fully matching, plus 24 partially matching documents found.

Latest appointments

  • Sobi appoints Torbjorn Hallberg as general counsel Sobi appoints Torbjorn Hallberg as general counsel

    Also sitting on the new team are Sobi's head of specialty care Norbert Oppitz, h ead of medical and scientific affairs Armin Reininger, h ead of haemophilia Philip Wood and

  • Anne Prener to lead Freeline Therapeutics Anne Prener to lead Freeline Therapeutics

    Freeline comprises some of the world’s leading experts in gene therapy, haemophilia and other debilitating disorders and I look forward to working closely with them to demonstrate the potential of ... She has also worked at Novo Nordisk as senir vice

  • Clark Health Communications expands team Clark Health Communications expands team

    Campbell will support and assist the team across its women’s health, gastroenterology and haemophilia accounts.

  • Shire’s Dr Armin Reininger moves to Sobi Shire’s Dr Armin Reininger moves to Sobi

    global medical affairs for haemophilia. ... Armin will apply his deep experience as an industry leader and academic in haemophilia to our team, as well as his global experience in medical scientific affairs to our stakeholders.”.

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 6 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics